Secondary Logo

Phillips Peter; Kwiatkowski, Margret B.; Copland, Michael; Craib, Kevin; Montaner, Julio
Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology: February 1st, 1999
CLINICAL SCIENCE: PDF Only
Free

Objective:To characterize the impact of combination antiretroviral therapy on the clinical and laboratory features of mycobacterial lymphadenitis, we conducted a retrospective chart review of HIV-related mycobacterial lymphadenitis at St. Paul's hospital between 1989 and 1997. Among 52 evaluable patients, 12 presented within 12 weeks of initiating combination antiretroviral therapy (group 1, n = 12); the others developed lesions while receiving no antiretrovirals, monotherapy, or a stable combination regimen of >12 weeks duration (group 2, n = 40).

Results:Group 1 patients had higher absolute CD4 lymphocyte counts (median, 150 versus 20 cells/mm3, respectively; p = .001) and hemoglobin levels (median, 113 versus 88 g/L, respectively; p = .002) at the time of mycobacterial diagnosis. Clinical comparison showed that group 1 patients were more likely to develop a draining sinus (50% versus 0%; p < .001), but less often to have weight loss (17% versus 74%; p < .0001) or disease which was disseminated (25% versus 70%; p = .04) or caused by Mycobacterium tuberculosis (0% versus 33%; p = .04).

Conclusions:Mycobacterial lymphadenitis developing within 12 weeks of initiating combination antiretroviral therapy is often localized Mycobacterium avium complex disease, associated with a relatively high CD4 count. The clinical course is often complicated by the development of a draining sinus. The close temporal association suggests that such treatment may unmask subclinical infection by enhancing the immune response to mycobacterial antigens.

Address correspondence and reprint requests to Peter Phillips, AIDS Research Program, St. Paul's Hospital, 667-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada; email: pphils@hivnet.ubc.ca.

Presented in part at the 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1997 [abstract 351].

Manuscript received July 9, 1998; accepted October 20, 1998.

© 1999 Lippincott Williams & Wilkins, Inc.